Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan 22;10:37. doi: 10.1186/s13287-019-1143-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 2 — Catalpol increases the expression of osteogenic-specific genes and proteins and activates Wnt/β-catenin signalling. a–c The expression of osteogenic-specific and Wnt/β-catenin signalling-related genes and proteins were assessed by qRT-PCR (a) and WB (b, c) at day 7 of osteogenic differentiation. d–i The expression of osteogenic-specific proteins COL1 (d, g) and RUNX2 (e, h) and β-catenin, the key protein of Wnt/β-catenin signalling (f, i), were assessed by IF. The data were confirmed by three repeated tests. The data are presented as the means ± SD. CA, catalpol; β-catenin (T), total β-catenin; β-catenin (N), nuclear β-catenin; LEF1 (N), nuclear LEF1; TCF1/7 (N), nuclear TCF1/7. *P < 0.05 compared with the control group, ^#P < 0.05 compared with the 10 μM catalpol treatment group